Alkermes price target lowered to $37 from $38 at Piper Sandler
PremiumThe FlyAlkermes price target lowered to $37 from $38 at Piper Sandler
11d ago
Alkermes backs FY24 financial expectations
Premium
The Fly
Alkermes backs FY24 financial expectations
12d ago
Alkermes reports Q3 adjusted EPS 72c, consensus 74c
Premium
The Fly
Alkermes reports Q3 adjusted EPS 72c, consensus 74c
12d ago
Alkermes to present clinical data from its Phase 1b study of ALKS 2680
PremiumThe FlyAlkermes to present clinical data from its Phase 1b study of ALKS 2680
1M ago
Mizuho says hard to tell yet how Centessa and Alkermes stack up in narcolepsy
Premium
The Fly
Mizuho says hard to tell yet how Centessa and Alkermes stack up in narcolepsy
2M ago
Alkermes initiates Vibrance-2 Phase 2 study evaluating ALKS 2680
Premium
The Fly
Alkermes initiates Vibrance-2 Phase 2 study evaluating ALKS 2680
2M ago
Is ALKS a Buy, Before Earnings?
PremiumPre-EarningsIs ALKS a Buy, Before Earnings?
4M ago
Alkermes price target lowered to $31 from $32 at JPMorgan
Premium
The Fly
Alkermes price target lowered to $31 from $32 at JPMorgan
4M ago
Jefferies says Neurocrine, Alkermes not seeing Sublocade-like impact on Medicaid
Premium
The Fly
Jefferies says Neurocrine, Alkermes not seeing Sublocade-like impact on Medicaid
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100